Key result
A prestans-based pharmacotherapy regimen showed no statistically significant differences compared to a monopril-based regimen in improving hemodynamic parameters, vascular age, and cardiovascular risk.
Why the study?
The influence of exogenous and pharmacogenetic factors on the effectiveness of combined pharmacotherapy in patients with stable angina, hypertension, and chronic heart failure was not fully evaluated.
Does a specific combined pharmacotherapy regimen improve hemodynamic parameters, lipid spectrum, and vascular age compared to an alternative regimen in patients with hypertension, stable angina, and chronic heart failure?
Does a specific combined pharmacotherapy regimen improve hemodynamic parameters, lipid spectrum, and vascular age compared to an alternative regimen in patients with hypertension, stable angina, and chronic heart failure?
Answers are grounded in this paper and cite their sources.
Two different comprehensive pharmacotherapy regimens yielded similar improvements in hemodynamics, lipid profiles, and cardiovascular risk in patients with multiple cardiovascular comorbidities.
The study assessed changes in hemodynamic and biochemical parameters, vascular age and 5-year cardiovascular risk on the background of complex pharmacotherapy in patients with stable angina I-III functional class (FC), hypertension of I-III degree, chronic heart failure (CHF) II-III FC taking into account the influence of exogenous and pharmacogenetic factors. The study included 200 patients aged 45 – 65 years with concomitant cardiovascular diseases: hypertension of I-III degree, stable angina (I-III FC), with CHF (II-III FC). Patients of the 1st group (100 patients) received prestans, carvedilol, hydrochlorothiazide, verospiron, preparations of acetylsalicylic acid, atorvastatin. Patients of the 2nd group (100 patients) received monopril (fosinopril sodium), carvedilol, amlodipine, hydrochlorothiazide, verospiron, preparations of acetylsalicylic acid, atorvastatin. In hypertensiology part of the study to the end of the observation period the positive dynamics of the main hemodynamic parameters found in both groups. The main indicators of lipid spectrum were improved. Assessment of the impact of pharmacogenetic factors on the effectiveness of the therapy showed no influence of ACE gene polymorphisms (rs4344) and CYP2D6 gene (rs1135840) for the basic hemodynamic parameters, whereas carriers of the genotype (G;G) of the gene CETP (rs4783961) in both groups was associated with a less significant increase of cholesterol of high density lipoproteins (HDL cholesterol) compared with carriers of the allele (A;A) and (A;G). The significant improvement noted in the analysis of the data of vascular age as an integral indicator of the state of the cardiovascular system, as well as a 5-year cardiovascular risk on the background of the combined pharmacotherapy. However, there were not detected statistically significant differences between 1-St and 2-nd groups
No takes yet. Share an insight, caveat, or question.
Корнилов et al. (2016) studied Hypertension, stable angina, and chronic heart failure (n=200). Prestans-based combined pharmacotherapy vs. Monopril-based combined pharmacotherapy was evaluated on Changes in hemodynamic and biochemical parameters, vascular age, and 5-year cardiovascular risk. A prestans-based pharmacotherapy regimen showed no statistically significant differences compared to a monopril-based regimen in improving hemodynamic parameters, vascular age, and cardiovascular risk.
Synapse has enriched 10 related papers. Consider them for comparative context: